pubmed-article:17574414 | rdf:type | pubmed:Citation | lld:pubmed |
pubmed-article:17574414 | lifeskim:mentions | umls-concept:C0166417 | lld:lifeskim |
pubmed-article:17574414 | lifeskim:mentions | umls-concept:C0001128 | lld:lifeskim |
pubmed-article:17574414 | lifeskim:mentions | umls-concept:C0220781 | lld:lifeskim |
pubmed-article:17574414 | lifeskim:mentions | umls-concept:C1883254 | lld:lifeskim |
pubmed-article:17574414 | lifeskim:mentions | umls-concept:C1707689 | lld:lifeskim |
pubmed-article:17574414 | lifeskim:mentions | umls-concept:C0243072 | lld:lifeskim |
pubmed-article:17574414 | pubmed:issue | 16 | lld:pubmed |
pubmed-article:17574414 | pubmed:dateCreated | 2007-7-30 | lld:pubmed |
pubmed-article:17574414 | pubmed:abstractText | The design and synthesis of novel series of 6-methyl-2-oxo-1,2,3,4-tetrahydro-pyrimidine-5-carboxylic acid (pyrimidone) derivatives that are high affinity ligands for peroxisome proliferators activated receptor gamma have been reported as a potential substitute of 2,4-thiazolidinedione head group. The FlexX docking and radioligand binding affinity of some promising compounds of this series is comparable to that of thiazolidinedione based antidiabetic drugs currently in clinical use. | lld:pubmed |
pubmed-article:17574414 | pubmed:language | eng | lld:pubmed |
pubmed-article:17574414 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:17574414 | pubmed:citationSubset | IM | lld:pubmed |
pubmed-article:17574414 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:17574414 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:17574414 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:17574414 | pubmed:status | MEDLINE | lld:pubmed |
pubmed-article:17574414 | pubmed:month | Aug | lld:pubmed |
pubmed-article:17574414 | pubmed:issn | 0960-894X | lld:pubmed |
pubmed-article:17574414 | pubmed:author | pubmed-author:KumarRakeshR | lld:pubmed |
pubmed-article:17574414 | pubmed:author | pubmed-author:RamachandranU... | lld:pubmed |
pubmed-article:17574414 | pubmed:author | pubmed-author:MittalAmitA | lld:pubmed |
pubmed-article:17574414 | pubmed:issnType | Print | lld:pubmed |
pubmed-article:17574414 | pubmed:day | 15 | lld:pubmed |
pubmed-article:17574414 | pubmed:volume | 17 | lld:pubmed |
pubmed-article:17574414 | pubmed:owner | NLM | lld:pubmed |
pubmed-article:17574414 | pubmed:authorsComplete | Y | lld:pubmed |
pubmed-article:17574414 | pubmed:pagination | 4613-8 | lld:pubmed |
pubmed-article:17574414 | pubmed:meshHeading | pubmed-meshheading:17574414... | lld:pubmed |
pubmed-article:17574414 | pubmed:meshHeading | pubmed-meshheading:17574414... | lld:pubmed |
pubmed-article:17574414 | pubmed:meshHeading | pubmed-meshheading:17574414... | lld:pubmed |
pubmed-article:17574414 | pubmed:meshHeading | pubmed-meshheading:17574414... | lld:pubmed |
pubmed-article:17574414 | pubmed:meshHeading | pubmed-meshheading:17574414... | lld:pubmed |
pubmed-article:17574414 | pubmed:meshHeading | pubmed-meshheading:17574414... | lld:pubmed |
pubmed-article:17574414 | pubmed:meshHeading | pubmed-meshheading:17574414... | lld:pubmed |
pubmed-article:17574414 | pubmed:meshHeading | pubmed-meshheading:17574414... | lld:pubmed |
pubmed-article:17574414 | pubmed:year | 2007 | lld:pubmed |
pubmed-article:17574414 | pubmed:articleTitle | Design and synthesis of 6-methyl-2-oxo-1,2,3,4-tetrahydro-pyrimidine-5-carboxylic acid derivatives as PPARgamma activators. | lld:pubmed |
pubmed-article:17574414 | pubmed:affiliation | Department of Pharmaceutical Technology, National Institute of Pharmaceutical Education and Research, Sector 67, S.A.S. Nagar, Punjab 160 062, India. rakvats@gmail.com | lld:pubmed |
pubmed-article:17574414 | pubmed:publicationType | Journal Article | lld:pubmed |
pubmed-article:17574414 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
http://linkedlifedata.com/r... | http://linkedlifedata.com/r... | pubmed-article:17574414 | lld:chembl |